Written by the pioneers of Viagra, the first blockbuster PDE inhibitor
drug.
Beginning with a review of the first wave of phosphodiesterase (PDE)
inhibitors, this book focuses on new and emerging PDE targets and their
inhibitors. Drug development options for all major human PDE families
are discussed and cover diverse therapeutic fields, such as
neurological/psychiatric, cardiovascular/metabolic, pain, and
allergy/respiratory diseases. Finally, emerging chemotherapeutic
applications of PDE inhibitors against malaria and other tropical
diseases are discussed.